Latest news and press releases about Pharvaris N.V. (PHVS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Price
| Price | $37.55 |
| Market Cap | $2.6B |
| Exchange | NASDAQ |
| Country | CH |
Valuation Ratios
| Price / Book | 7.57 |
| EV / EBITDA | -11.82 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -61.24% |
| Return on Invested Capital | -60.72% |
| Return on Assets | -52.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARDX · BCRX · IMNM · MAZE · NTLA · ORIC · SYRE
Explore sector: Healthcare · Biotechnology
More sections of PHVS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks